相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells
C. Straube et al.
LEUKEMIA (2007)
Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib
Marion Subklewe et al.
HUMAN IMMUNOLOGY (2007)
Higher numbers of blood CD14+ cells before starting conditioning regimen correlate with greater risk of acute graft-versus-host disease in allogeneic stem cell transplantation from related donors
Mario Arpinati et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation
Juan Mateos-Mazon et al.
HAEMATOLOGICA (2007)
Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications
Anjli Kukreja et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
CEACAM1 (CD66a) promotes human monocyte survival via a phosphatidylinositol 3-kinase- and AKT-dependent pathway
Qigui Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation
Alessio Nencioni et al.
BLOOD (2006)
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines
B Blanco et al.
BLOOD (2006)
Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells
A Nencioni et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
P Perez-Galan et al.
BLOOD (2006)
Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity
K Sun et al.
BLOOD (2005)
Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer
MM Mortenson et al.
LUNG CANCER (2005)
Dynamic changes in Mcl-1 expression regulate macrophage viability or commitment to apoptosis during bacterial clearance
HM Marriott et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy
A Curti et al.
LEUKEMIA & LYMPHOMA (2004)
Approval summary for bortezomib for injection in the treatment of multiple myeloma
PF Bross et al.
CLINICAL CANCER RESEARCH (2004)
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib
K Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Clinical update: proteasome inhibitors in hematologic malignancies
P Richardson
CANCER TREATMENT REVIEWS (2003)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
T Hideshima et al.
BLOOD (2003)
Human CD34(+) blood cells induce T-cell unresponsiveness to specific alloantigens only under costimulatory blockade
M Arpinati et al.
EXPERIMENTAL HEMATOLOGY (2003)
Antigen presentation in graft-vs-host disease
WD Shlomchik
EXPERIMENTAL HEMATOLOGY (2003)
Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis
RZ Orlowski et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus
P Blanco et al.
SCIENCE (2001)
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer
SA Shah et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2001)
分享论文
